PD717
MORPHOFUNCTIONAL PHENOTYPE (MFP) IN AMBULATORY CANCER PATIENTS WITH DISEASE-RELATED MALNUTRITION (DRM): ASSOCIATIONS WITH SARCOPENIA AND GLOBAL LEADERSHIP INICIATIVE MALNUTRITION (GLIM) CRITERIA SEVERITY: ANYVIDA STUDY SUBANALYSIS
M. C. Dassen Llorca1 on behalf of AnyVida Group, A. Castro Luna2 on behalf of AnyVida Group, I. Gonzalo Montesinos3,* on behalf of AnyVida Group, M. Crespo Yanguas1 on behalf of AnyVida Group, S. Gago Gago3 on behalf of AnyVida Group, G. Moreno Segura2 on behalf of AnyVida Group, M. D. C. Bernal Asensio3 on behalf of AnyVida Group, C. Calderón Sánchez1 on behalf of AnyVida Group, B. Cánovas Gaillemín2 on behalf of AnyVida Group, R. Fernández Jiménez4 on behalf of AnyVida Group, J. M. García Almeida4 on behalf of AnyVida Group on behalf of AnyVida Group
1Endocrinology and Nutrition, Fundación Jiménez Díaz, Madrid, 2Endocrinology and Nutrition, Hospital Universitario de Toledo, Toledo, 3Endocrinology and Nutrition, Hospital Universitario de Fuenlabrada, Fuenlabrada, 4Endocrinology and Nutrition, Hospital Universitario Virgen de la Victoria, Málaga, Spain
Rationale: Sarcopenia (Sarc) and DRM coexist in cancer patients, the MFP associated with their combination remains poorly characterized. Analyze the relationship between Sarc and GLIM-defined DRM severity to identify the clinical and MFP with concomitant sarcopenia and severe DRM
Methods: Ambulatory cancer patients with DRM who underwent nutritional and morphofunctional assessment were included. Sarc was defined according to European Working Group on Sarcopenia in Older People (EWGSOP2) criteria and DRM severity according to GLIM. We analized the association with Sarc and GLIM severity and individual GLIM components. We stratified patients: non-Sarc+moderate GLIM, non-Sarc+severe GLIM,
sarc+moderate GLIM, and Sarc+severe GLIM
Results: Patients with severe GLIM were more likely to have Sarc compared to moderate GLIM (χ²=6.81; p=0.009; OR=1.94; 95% CI 1.17–3.20). Severe muscle mass loss showed the strongest association with Sarc (χ²=19.1; p<0.001; OR=3.15; 95% CI 1.86–5.34) and severe weight loss (χ²=9.97; p=0.002; OR=2.14; 95% CI 1.33–3.45). Low BMI was not associated with Sarc (p=0.744)
Image:
Conclusion: Ambulatory cancer patients with DRM, severe GLIM criteria is associated with a higher likelihood of sarcopenia, this relationship appears to be driven mainly by severe muscle mass loss and severe weight loss. Moreover, the coexistence of sarcopenia and severe GLIM-defined DRM identifies the most morphofunctionally compromised phenotype, supporting the combined use of both constructs for better risk stratification in clinical practice
References: Cruz-Jentoft AJ, et al. Age Ageing. 2019
Prado CM, et al. Sarcopenia and chemotherapy toxicity in cancer patients
Shachar SS, et al. Prognostic value of sarcopenia in oncology
Disclosure of Interest: None declared